C-Type Natriuretic Peptide

What is C-Type Natriuretic Peptide?

C-type natriuretic peptide (CNP) is a 22-amino-acid endogenous peptide containing the same 17-residue intramolecular disulfide ring (Cys6–Cys22) that defines all natriuretic peptides. It is the third and structurally most ancestral member of the family, identified in 1990 by Tetsuji Sudoh, Naoto Minamino, Kenji Kangawa, and Hisayuki Matsuo at the National Cardiovascular Center Research Institute and Miyazaki Medical College in Japan — the same laboratory that had isolated ANP (1984) and BNP (1988). CNP is encoded by the NPPC gene on chromosome 2q37 and is synthesized as a 126-amino-acid precursor (preproCNP) processed first by signal peptidase to proCNP, then by the proprotein convertase furin to a 53-amino-acid intermediate (CNP-53) and the bioactive 22-residue C-terminal fragment (CNP-22). Both CNP-53 and CNP-22 circulate, but CNP-22 is the dominant active form; CNP-53 is enriched in tissue (particularly endothelium and brain) and may serve as a slower-release reservoir. The defining biology of CNP is the receptor it engages. While ANP and BNP signal predominantly through natriuretic peptide receptor A (NPR-A / GC-A / NPR1), CNP signals almost exclusively through natriuretic peptide receptor B (NPR-B / GC-B / NPR2), a structurally homologous single-pass membrane guanylyl cyclase that generates intracellular cGMP from GTP upon ligand binding. NPR-C, the natriuretic peptide clearance receptor, binds all three natriuretic peptides without activating cGMP and provides receptor-mediated clearance shared across the family. Tissue distribution is also distinct: CNP is the natriuretic peptide of the endothelium, of the growth-plate chondrocyte, of the central nervous system (where CNP-22 and CNP-53 are abundant in cerebrospinal fluid), and of the female reproductive tract — but it is only weakly expressed in the heart. As a result, plasma CNP concentrations are very low compared with ANP and BNP, and CNP's physiological footprint is paracrine and local rather than systemic-endocrine. Loss-of-function mutations in NPPC or NPR2 cause acromesomelic dysplasia type Maroteaux (AMDM), a recessive short-stature disorder; gain-of-function NPR2 mutations produce overgrowth syndromes with very tall stature; and a CNP analog (vosoritide / Voxzogo) was FDA-approved in 2021 as the first targeted therapy for achondroplasia.

What C-Type Natriuretic Peptide Is Investigated For

CNP is best understood as the natriuretic peptide that broke the cardiac frame. ANP and BNP are released from atrial and ventricular cardiomyocytes in response to wall stretch, signal through NPR-A, and act systemically on kidney and vasculature; CNP is released from endothelium, chondrocytes, brain, and reproductive tract, signals through NPR-B, and acts paracrinely on neighboring cells. Plasma CNP concentrations are orders of magnitude lower than ANP or BNP, and CNP is not used as a circulating biomarker for heart failure — its biology lives in tissue, not blood. The therapeutic story is unusual for the natriuretic peptide family because CNP's most successful clinical translation is not cardiovascular at all: vosoritide (BioMarin's Voxzogo), a modified neprilysin-resistant CNP analog, was FDA-approved in November 2021 for achondroplasia in children with open growth plates, expanded in October 2023 down to 4 months of age, and stands as the first pharmacological therapy ever approved for this condition. The mechanistic case rested on more than two decades of work showing that CNP-NPR-B-cGMP signaling is the master positive regulator of endochondral ossification — Chusho's 2001 PNAS paper showing that CNP knockout mice develop dwarfism, Tamura's mechanistic dissection of NPR-B and PKG-II in chondrocytes, Yasoda's 2004 Nature Medicine paper showing that chondrocyte-targeted CNP overexpression rescues the achondroplasia phenotype in Fgfr3-mutant mice, and Bartels' 2004 demonstration that loss-of-function NPR2 mutations cause acromesomelic dysplasia type Maroteaux in humans. The matching gain-of-function story (Hannema et al. 2013) showed that activating NPR2 mutations cause extreme tall stature without skeletal deformity. Beyond bone, the endothelial CNP story has matured substantially since Moyes and Hobbs 2014 (J Clin Invest), which used endothelial-specific CNP knockout mice to show that endothelial-derived CNP maintains vascular homeostasis, controls blood pressure, and protects against atherosclerosis — a paracrine vascular role that is distinct from the systemic-endocrine cardiovascular roles of ANP and BNP. CNP itself is not a consumer or wellness peptide; clinical translation has been through the engineered analog vosoritide rather than native CNP infusion.

History & Discovery

CNP was identified in 1990 by Tetsuji Sudoh, Naoto Minamino, Kenji Kangawa, and Hisayuki Matsuo at the National Cardiovascular Center Research Institute and Miyazaki Medical College — the same Japanese laboratory that had isolated ANP in 1984 and BNP in 1988. The initial 1990 BBRC paper purified CNP-22 from porcine brain (the same tissue source that had earlier yielded BNP), sequenced it, and showed it to be the third structurally distinct member of the natriuretic peptide family. The peptide preserves the 17-residue intramolecular disulfide ring shared by ANP and BNP but lacks the C-terminal tail beyond the ring — a structural feature that, together with the N-terminal sequence, dictates its receptor selectivity for NPR-B over NPR-A. The CNP-53 form was identified shortly afterward as a furin-processed intermediate enriched in tissue (particularly endothelial and brain) and circulating at lower concentrations than CNP-22. The receptor framework had been put in place a year earlier with the 1989 cloning of NPR-A (Chinkers, Garbers et al., Nature 1989) and NPR-B (Schulz, Singh, Garbers, Cell 1989) — both demonstrating the paradigm-defining receptor-cyclase architecture. The receptor-selectivity grammar (ANP and BNP for NPR-A; CNP for NPR-B) was formalized by Suga, Nakao, and colleagues (Endocrinology 1992), establishing the pharmacological framework that has organized natriuretic peptide research since. The physiological focus of CNP research shifted decisively from cardiovascular to skeletal biology over the following decade. Tissue-distribution studies showed that CNP was only weakly expressed in the heart (in stark contrast to ANP and BNP) but was abundant in vascular endothelium, growth-plate chondrocytes, brain, and the female reproductive tract — and that plasma CNP concentrations were orders of magnitude lower than ANP or BNP, consistent with paracrine rather than systemic-endocrine signaling. The chondrocyte/bone-growth story crystallized with Chusho and colleagues' 2001 PNAS paper showing that CNP-knockout mice develop severe dwarfism and early death, and was extended by Miyazawa, Tamura, and colleagues (Endocrinology 2002) demonstrating the requirement for cGMP-dependent protein kinase II (PKG-II) downstream of NPR-B in chondrocyte differentiation. Yasoda and colleagues (Nat Med 2004) then provided the proof-of-concept for therapeutic CNP-pathway activation in achondroplasia: chondrocyte-targeted CNP overexpression rescued the Fgfr3-mutant achondroplasia phenotype in mice via cGMP-mediated antagonism of MAPK signaling. The matching human genetics arrived the same year: Bartels and colleagues (Am J Hum Genet 2004) identified NPR-B (NPR2) loss-of-function mutations as the genetic cause of acromesomelic dysplasia type Maroteaux, the recessive short-stature disorder. The genotype-phenotype gradient was completed by Hisado-Oliva et al. (J Clin Endocrinol Metab 2015) showing that heterozygous NPR2 loss causes disproportionate short stature, and by Hannema et al. (J Clin Endocrinol Metab 2013) showing that activating NPR2 mutations cause extreme tall stature. The vascular role of CNP, long suspected from in vitro studies of endothelial expression and smooth-muscle relaxation, was pinned down at the genetic level by Moyes, Hobbs, and colleagues (J Clin Invest 2014), whose endothelial-cell-specific CNP knockout mice demonstrated that endothelium-derived CNP maintains basal blood pressure, supports endothelium-dependent vasorelaxation, and protects against atherosclerosis. Reproductive biology of CNP — granulosa-cell CNP maintaining oocyte meiotic arrest — was characterized in parallel through the 2000s and 2010s. The therapeutic translation has been driven entirely by engineered analogs rather than native CNP. BioMarin Pharmaceutical developed BMN-111 / vosoritide as a 39-residue modified CNP analog with an N-terminal extension that resists neprilysin cleavage while preserving NPR-B agonism, advanced it through Phase 1, 2, and 3 studies in children with achondroplasia (Savarirayan et al., Lancet 2020), and obtained FDA approval as Voxzogo in November 2021 (children aged 5+ with open epiphyses), with expansion to ages 4 months and older in October 2023 — the first pharmacological therapy ever approved for achondroplasia. Longer-acting CNP-fusion proteins (TransCon CNP / navepegritide and others) have continued to advance through clinical development with weekly dosing schedules, and additional CNP-pathway approaches in skeletal dysplasias and cardiovascular disease remain active areas of translation.

How It Works

CNP is the third member of the natriuretic peptide family — the lesser-known cousin of ANP and BNP. While ANP and BNP are heart hormones that tell the kidneys to dump salt and water, CNP works locally rather than systemically, mostly inside blood vessels, in the cartilage growth plates of children's bones, and in the brain. Its single most important job is to drive long-bone growth: chondrocytes (the cartilage cells at the ends of growing bones) need the CNP signal to keep dividing and stretching the bone longer. If CNP or its receptor doesn't work, you get short stature; if the receptor is over-active, you get unusually tall stature. The drug vosoritide (Voxzogo) is a lab-modified version of CNP that doesn't get broken down as quickly — it's used to help children with achondroplasia grow taller. CNP also helps blood vessels stay relaxed and healthy, but it doesn't act as a strong systemic blood-pressure or fluid-balance hormone the way ANP and BNP do.

CNP is encoded by the NPPC gene on chromosome 2q37 and synthesized as a 126-amino-acid preproCNP precursor. After signal-peptide cleavage, the resulting proCNP is processed by the proprotein convertase furin at a paired-basic cleavage site to release a 53-amino-acid intermediate (CNP-53, residues 51–103) and ultimately the 22-residue C-terminal fragment (CNP-22, residues 82–103). Both CNP-53 and CNP-22 are biologically active, with CNP-53 enriched in endothelial and brain tissue (where it may serve as a slower-release storage form) and CNP-22 dominant in circulation. The 17-residue disulfide ring (Cys6–Cys22) that is the defining structural signature of all natriuretic peptides is required for receptor binding; CNP lacks the C-terminal 'tail' beyond the ring that ANP and BNP possess. CNP signals predominantly through natriuretic peptide receptor B (NPR-B; also designated GC-B, NPR2, or guanylyl cyclase-B), a single-transmembrane receptor with an intrinsic intracellular guanylyl cyclase domain — the structural paradigm shared with NPR-A and first established in 1989 (Schulz, Singh, Garbers, Cell 1989; Chinkers, Garbers et al., Nature 1989). CNP binds NPR-B with much higher affinity than ANP or BNP — a selectivity profile demonstrated by Suga, Nakao, and colleagues (Endocrinology 1992). NPR-B activation triggers receptor dimerization, ATP-dependent conformational rearrangement of the kinase-homology domain, and activation of the cytosolic guanylyl cyclase catalytic domain, generating cGMP from GTP. Downstream cGMP activates protein kinase G (predominantly PKG-II in chondrocytes), modulates cyclic-nucleotide-gated ion channels, and is hydrolyzed by cGMP-specific phosphodiesterases. NPR-C (the clearance receptor) binds CNP, ANP, and BNP without activating cGMP and provides receptor-mediated peptide internalization and degradation; the metalloendopeptidase neprilysin provides the parallel proteolytic clearance pathway. Plasma half-life of CNP-22 is approximately 2–3 minutes — too short to support systemic-endocrine signaling, which is consistent with CNP's tissue-paracrine biology. The physiological actions of CNP fall into four major categories. (1) Skeletal: CNP-NPR-B-cGMP-PKG-II signaling in growth-plate chondrocytes is the master positive regulator of endochondral ossification. Chusho and colleagues (PNAS 2001) showed that CNP-knockout mice develop severe dwarfism and early death; complementary work established that PKG-II is required downstream of NPR-B for chondrocyte proliferation and differentiation (Miyazawa et al., Endocrinology 2002). Yasoda and colleagues (Nat Med 2004) demonstrated that chondrocyte-targeted CNP overexpression rescues the achondroplasia phenotype in Fgfr3-mutant mice — proof of concept for vosoritide. The mechanistic cross-talk is that cGMP-PKG signaling inhibits the RAF–MEK–ERK arm of the MAPK cascade downstream of FGFR3, antagonizing the over-active FGFR3-MAPK signal that causes achondroplasia. The matching human genetics confirm pathway dosage: homozygous NPPC or NPR2 loss-of-function causes acromesomelic dysplasia type Maroteaux (Bartels et al., Am J Hum Genet 2004), heterozygous NPR2 loss causes disproportionate short stature (Hisado-Oliva et al., J Clin Endocrinol Metab 2015), and activating NPR2 mutations cause extreme tall stature without skeletal deformity (Hannema et al., J Clin Endocrinol Metab 2013). (2) Vascular: endothelial cells are the dominant vascular source of CNP, and endothelium-specific CNP deletion produces endothelial dysfunction, hypertension, and accelerated atherosclerosis (Moyes, Hobbs et al., J Clin Invest 2014), establishing a paracrine endothelial-to-vascular-smooth-muscle CNP signal that complements nitric oxide and prostacyclin in maintaining basal vascular tone. (3) Central nervous system: CNP-22 and CNP-53 are abundant in brain tissue and cerebrospinal fluid, with regulation distinct from peripheral plasma CNP (Espiner, Yandle et al., Peptides 2011); CNS roles include neuronal signaling, neuroprotection, and CSF homeostasis, though the clinical implications remain largely investigational. (4) Reproductive: granulosa-cell CNP signaling at cumulus-oocyte NPR-B maintains oocyte meiotic arrest until the LH surge at ovulation collapses the CNP signal and permits meiotic resumption. Clearance of CNP occurs through three parallel routes: NPR-C-mediated receptor internalization and lysosomal degradation; proteolytic degradation by neprilysin (the dominant route in plasma); and renal filtration. Therapeutic CNP-pathway analogs are engineered around these clearance vulnerabilities — vosoritide's N-terminal extension blocks neprilysin cleavage while preserving NPR-B agonism, and longer-acting CNP-fusion proteins (TransCon CNP / navepegritide, others) extend half-life through PEG or protein-fusion strategies suitable for less-frequent-than-daily dosing.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about C-Type Natriuretic Peptide:

• 01Whether long-term CNP-pathway activation (with long-acting analogs such as navepegritide / TransCon CNP, or with other engineered CNP analogs in development) yields the same magnitude of growth-velocity benefit as daily vosoritide and what the long-term safety profile looks like at scale.
• 02Whether CNP-pathway therapeutics meaningfully reduce the non-stature complications of achondroplasia — foramen magnum stenosis, spinal stenosis, sleep apnea, otitis media — beyond their effect on linear bone growth.
• 03Whether CNP-pathway activation has therapeutic value in cardiovascular disease in adults beyond what neprilysin inhibition (Entresto) already provides, particularly in atherosclerosis, pulmonary hypertension, and heart failure with preserved ejection fraction.
• 04The clinical relevance of CNS CNP biology — whether central CNP-NPR-B signaling can be therapeutically engaged for neuroprotection, cerebrospinal-fluid disorders, or neuropsychiatric indications, given the abundance of CNP and NPR-B in the brain.
• 05The role of CNP in human reproductive medicine — whether CNP-pathway modulation has clinical utility in fertility treatment (oocyte maturation, in vitro maturation protocols) given the granulosa-cell-CNP / oocyte-meiotic-arrest biology.
• 06Whether the CNP-53 tissue-enriched form has biology distinct from CNP-22 that could be therapeutically exploited, beyond serving as a slower-release storage form.
• 07Whether CNP genetics (NPPC and NPR2 polymorphisms) explain a meaningful fraction of normal-range height variation in unselected populations, beyond the rare-variant phenotypes (AMDM, overgrowth) already characterized.

Forms & Administration

Native CNP is not formulated or approved as a therapeutic in any major jurisdiction. Research applications use synthetic CNP-22 (and occasionally CNP-53) for in vitro NPR-B binding and signaling assays, ex vivo tissue pharmacology, and short experimental infusions in animal and limited human research settings. The 2–3 minute plasma half-life of native CNP makes any non-IV systemic administration mechanistically impractical. The clinically translated forms of CNP biology are engineered analogs designed to resist neprilysin-mediated clearance and extend half-life: vosoritide (Voxzogo) is a 39-residue modified CNP analog given as a once-daily subcutaneous injection in children with achondroplasia (covered as a separate peptide entry), and longer-acting CNP-fusion proteins such as navepegritide (TransCon CNP) are advancing through clinical development with weekly dosing schedules. There is no oral, transdermal, or outpatient form of native CNP, and compounded CNP from peptide marketplaces has no validated clinical use.

Common Questions

Who C-Type Natriuretic Peptide Is NOT For

Drug & Supplement Interactions

Native CNP and CNP-pathway analogs are cleared by neprilysin-mediated proteolysis, NPR-C-mediated receptor internalization, and renal filtration, with no meaningful hepatic cytochrome P450 metabolism — so classical CYP-based pharmacokinetic drug interactions are not expected. The clinically relevant interactions are pharmacodynamic. Neprilysin inhibitors (sacubitril, the active component of sacubitril/valsartan / Entresto) raise endogenous CNP levels by blocking its proteolytic clearance, in addition to raising ANP and BNP. Combining a neprilysin inhibitor with exogenous CNP or CNP analogs could amplify NPR-B and NPR-A signaling beyond what either strategy delivers alone; this combination is not a standard clinical practice and would require specialist supervision. Vasodilators and antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, organic nitrates, hydralazine, alpha-blockers, PDE5 inhibitors) can produce additive blood-pressure lowering when combined with CNP-pathway activation through NPR-B-cGMP vascular signaling, particularly in volume-depleted or already-hypotensive patients. The vosoritide label addresses this risk through dosing recommendations (administration with a meal or snack and adequate hydration); for native CNP in research settings, the same principle applies. In pediatric achondroplasia patients on vosoritide, drug-interaction concerns are limited because most children are not on extensive concomitant medications; the dominant safety considerations are injection-site reactions and transient asymptomatic blood-pressure reduction. For specific dose adjustment and interaction guidance, the operative reference is the current vosoritide prescribing information and institutional protocol — not a general CNP description.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions